Fig. 5From: Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directionsNovel immunotherapies in SCLC. AÂ TIM-3, TIGIT and LAG3 have been proven to be novel targets in SCLC. BÂ CAR T cell therapy, CAR-NK cell therapy has also captured attention as a potential immunotherapeutic strategy in SCLC.Back to article page